Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 30, 2003 Jeff Hwang	Trinity Scores With HIV Test FDA approval of 10-minute HIV test sends Trinity shares soaring.
Chemistry World July 3, 2012 Andrew Turley	US approves HIV home test kit The 'OraQuick' kit from US diagnostics firm OraSure, is already in use by clinics, but until now the company has not been allowed to market it for home use.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool May 15, 2007 Mike Havrilla	Risky Bet OraSure Thing? The company strides forward to offer quick, less invasive methods of testing for disease and drugs. Investors, take note.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool December 31, 2003 Alyce Lomax	Nothing Decisive About Encysive Analyst initiation boosts the stock during the slow holiday week.
The Motley Fool September 22, 2006 Brian Lawler	Healthy Rec for OraSure The CDC recommends that HIV testing become routine for everyone aged 13-64. Investors, this is good news for medical diagnostic companies.
The Motley Fool January 22, 2004 Rich Smith	Symantec Buys Itself Symantec reports great profits and a debatable share buyback decision.
The Motley Fool May 5, 2004 Charly Travers	Growing Profits at Connetics A broad product line is leading to sustainable growth for the small drug developer.
The Motley Fool September 30, 2008 Brian Lawler	No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
The Motley Fool June 21, 2007 Brian Lawler	Pfizer Gets Held Up The FDA issues an approvable letter for its novel HIV compound. Investors, take note.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool April 8, 2004 Charly Travers	Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool March 24, 2004 W.D. Crotty	Risky Red Hat Red Hat has perfect performance figured into its stock price.
InternetNews May 21, 2004 Paul Shread	Blue Nile Gets A Rousing Welcome The market for IPOs has been struggling lately, but not so for Blue Nile.
The Motley Fool February 20, 2004 Bill Mann	Things Left Unsaid A company puts its best foot forward in a press release, but old releases can tell a different story.
InternetNews July 23, 2004 Paul Shread	Microsoft, Amazon Add to Slowdown Fears Weak earnings add to fears of an economic slowdown... Nasdaq hits fresh lows for the year... Broadcom, Gateway beat estimates... DoubleClick plunges...
The Motley Fool May 21, 2004 W.D. Crotty	It's National Burger Month! With sales at hamburger chains soaring, it's worth taking a look at the burger stocks.
BusinessWeek November 10, 2003 Arlene Weintraub	Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk
American Journal of Nursing March 2010 Bradley-Springer et al.	Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
The Motley Fool July 16, 2011 Melly Alazraki	HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool April 16, 2004 Rich Smith	DoubleClick's Pinched Penny Rounding earnings per share can lay traps for unwary investors. Online advertiser DoubleClick becomes a good lesson in why it is best to think of those little ticker symbols scrolling by as pieces of companies rather than little ticker symbols.
The Motley Fool April 21, 2004 Rich Smith	Career Education's Big Lesson The online educator Career Education rakes in stellar earnings, exceeding analyst estimates again.
The Motley Fool May 20, 2004 Steven Mallas	Intuit's Taxing Quarter Net earnings declined and Q4 could see a loss. What should an investor's intuition be saying?
The Motley Fool March 11, 2004 Ben McClure	Quality Earnings Count Here are three telltale signs of strong earnings. This reporting period, it's worthwhile taking a peek behind the earnings. Here are three telltale signs of earnings "quality" to guide your stock picks.
InternetNews June 16, 2004 Paul Shread	Analyst Predicts Adobe Slowdown CS First Boston thinks Adobe's run may be about over.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
Chemistry World March 1, 2012 Simon Hadlington	Quicklime provides a hot way for rapid HIV detection US researchers have developed a rapid testing kit for HIV, which uses nothing more sophisticated than quicklime to power it.
The Motley Fool June 16, 2004	Understanding "Multiples" Understanding multiples can help you evaluate a stock's attractiveness.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
Chemistry World September 3, 2009 Sarah Houlton	New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine.
The Motley Fool March 29, 2004 Rick Aristotle Munarriz	Consumer Electronics: Unplugged Best Buy and Circuit City go head-to-head with same-day earnings releases.
American Family Physician July 15, 2004 Joel E. Gallant	HIV Counseling, Testing, and Referral By the year 2005, the CDC seeks to achieve the following: reduce annual new HIV infections from the current estimated 40,000 cases to 20,000 cases through the use of interventions such as counseling, HIV testing, and referral
The Motley Fool April 1, 2004 Rick Aristotle Munarriz	Bed Bath & Beyond Belief The home specialist reports another quarter of clean earnings.
The Motley Fool August 9, 2004 Chris Mallon	Through the Earnings Looking Glass Look-through earnings provide a new and insightful view of your stock portfolio.
Chemistry World July 8, 2010 Sarah Houlton	Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against.
The Motley Fool April 19, 2004 Seth Jayson	Lexmark Inks More Profits The printer maker lives up to its buzz and continues to increase earnings.
The Motley Fool June 8, 2004 W.D. Crotty	An Unlucky Alliance Slot-machine maker Alliance Gaming is getting hammered, but it's no loser.
The Motley Fool July 6, 2004 Alyce Lomax	United Natural Gets Slammed Investors viewed the company as an unhealthy investment today, pushing the stock down as much as 19% after the organic food supplier warned it will come in shy of profit expectations.
The Motley Fool March 23, 2004 W.D. Crotty	Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks.
The Motley Fool January 28, 2011 Brian Orelli	Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result.
Reason July 2004 Caroline Waters	Bloody Shame Unnecessary regulations are making American blood banks run dry.
The Motley Fool January 30, 2004 Alyce Lomax	No Hollywood Star Competitive concerns loom over Hollywood Entertainment's long-term growth plans.
InternetNews June 15, 2004 Paul Shread	Oracle Investors Get Picky Oracle beat estimates after the close on Tuesday, but investors proved to be tough to please.
The Motley Fool December 12, 2003 Carla Pasternak	Adobe's Off to the Races The company's the odds-on favorite among software makers.